Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
PHASE3CompletedINTERVENTIONAL
Enrollment
407
Participants
Timeline
Start Date
October 31, 2015
Primary Completion Date
May 31, 2018
Study Completion Date
May 31, 2018
Conditions
B-cell Non Hodgkin's Lymphoma
Interventions
DRUG
HLX01
DRUG
Rituximab
DRUG
CHOP
Trial Locations (1)
Unknown
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
All Listed Sponsors
lead
Shanghai Henlius Biotech
INDUSTRY
NCT02787239 - Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | Biotech Hunter | Biotech Hunter